Overview
Phenibut FAA is the free amino acid form of beta-phenyl-gamma-aminobutyric acid. Compared with phenibut HCl, it lacks the hydrochloride salt and is often marketed as less acidic and more suitable for sublingual use. The active molecule is still phenibut, so the relevant safety literature on dependence, intoxication, and withdrawal still applies.
The mechanism is driven primarily by GABA-B receptor agonism after the compound reaches the central nervous system. Some users describe a different onset or mouthfeel with FAA, but there is little rigorous human pharmacokinetic evidence proving superior sublingual bioavailability. Practical differences may come from formulation, particle size, pH, dose measurement, and user expectations.
Phenibut FAA is not FDA-approved and should not be marketed as a dietary supplement in the United States. The free amino acid form does not make phenibut safer, non-addictive, or appropriate for daily anxiety management. Case reports of phenibut harm should be applied broadly unless a study specifically proves a formulation-specific safety difference.
This guide focuses on what changes with the FAA form and what does not. The main message is simple: route and salt form may influence comfort or onset, but they do not erase phenibut's CNS depressant profile, withdrawal risk, interaction hazards, or need for careful measurement.
Quick facts
- Mechanism
- Free amino acid phenibut with GABA-B activity
- Primary use
- Anxiolytic and sleep research
- Evidence
- limited
- FDA
- Not approved
- Route
- Oral or sublingual administration
- Typical results
- Similar phenibut effects with formulation-dependent onset
Chemical information
Phenibut FAA has the same base molecule as phenibut, with molecular mass 179.22 g/mol and formula C10H13NO2. The difference from phenibut HCl is salt state, not a new pharmacological target.
How Phenibut FAA works
Phenibut FAA delivers phenibut without the hydrochloride salt. Once absorbed, the active pharmacology is expected to be the same: GABA-B receptor agonism with sedative, anxiolytic, and muscle-relaxant effects. The FAA form may be easier for some users to hold sublingually, but there is no strong published human evidence that this route reliably prevents tolerance, dependence, or delayed adverse effects.
The free amino acid form changes the salt chemistry, not the core drug target. GABA-B activation decreases neuronal excitability and can feel calming, but repeated stimulation can trigger adaptation. Users who switch from HCl to FAA may accidentally change active dose because products are weighed differently and purity varies.
Sublingual marketing should be treated skeptically. Absorption through the oral mucosa depends on solubility, contact time, pH, and formulation. Swallowed material still behaves like oral phenibut. Without human PK studies comparing FAA, HCl, oral, and sublingual dosing, claims of faster or cleaner effects remain anecdotal.
The danger profile remains phenibut's danger profile: delayed onset, compulsive redosing, tolerance, severe withdrawal after repeated use, and additive sedation with other depressants. The formulation may reduce acidity-related stomach discomfort, but it is not a safety upgrade in the ways that matter most.
- Same active drug: FAA still delivers phenibut and should be risk-assessed like phenibut
- GABA-B signaling: Produces anxiolytic and sedative effects through inhibitory neurotransmission
- Formulation difference: Free amino acid form may be less acidic than HCl powder
- Sublingual uncertainty: Better sublingual bioavailability is plausible but not well proven in humans
- Dependence risk: Salt form does not prevent tolerance or withdrawal
- Measurement risk: Powder potency and molecular form can confuse dose conversion
Pharmacokinetics
No robust peer-reviewed human PK comparison confirms that phenibut FAA has superior sublingual bioavailability over phenibut HCl. Treat onset, duration, and half-life claims as approximate unless tied to validated analytical data.
| Parameter | Value | Significance |
|---|---|---|
| Active compound | Phenibut | Core effects and risks remain the same |
| Route | Oral or sublingual | Sublingual advantage is not well quantified |
| Half-life | About 5 hours reported for phenibut | FAA-specific human half-life is not established |
| Onset | Variable | Delayed effects can encourage unsafe redosing |
| Metabolism | Limited human data | Interaction prediction remains uncertain |
| Elimination | Renal contribution reported | Kidney function may matter for exposure |
Dosing & administration
There is no FDA-approved dosing for phenibut FAA. Because FAA and HCl differ by salt weight, gram-for-gram substitution can unintentionally change active exposure. Research-use powders also require accurate milligram scales and verified purity.
Users sometimes choose FAA for sublingual use, but the evidence base does not support treating it as a separate, safer drug. Frequency limits matter more than route. Repeated use across days is the pattern most associated with dependence and withdrawal.
Anyone already using phenibut daily should seek medical help before stopping abruptly. Withdrawal management can be complex and may require clinician-directed tapering or medications used in published case reports.
Important: These dosing ranges are not FDA-approved. Any use should be under qualified medical supervision.
Side effects & safety
Phenibut FAA should be approached with the same caution as phenibut HCl. It is unapproved in the United States, may be sold through poorly regulated channels, and can produce serious withdrawal after chronic use.
Common
- • Drowsiness
- • Dizziness
- • Nausea or stomach discomfort
- • Headache
- • Impaired coordination
- • Next-day grogginess
Serious / potential risks
- • Dependence and withdrawal
- • Seizures during severe withdrawal
- • Delirium or hallucinations
- • Respiratory depression with sedatives
- • Overdose from inaccurate powder weighing
Drug interactions
Interactions should be considered equivalent to phenibut unless good evidence proves otherwise.
| Medication | Interaction | Recommendation |
|---|---|---|
| Alcohol | Additive CNS depression | Avoid |
| Benzodiazepines | Increased sedation and withdrawal complexity | Avoid outside medical care |
| Opioids | Potential respiratory depression | Avoid |
| Z-drugs | Overlapping sleep and amnesia effects | Avoid combining |
| Baclofen | Overlapping GABA-B agonism | Use only under medical supervision |
Storage & handling
Lyophilized (powder)
- • Store at -20°C to 4°C (freezer or refrigerator)
- • Protect from light and moisture
- • Stable for 12–24 months when stored properly
- • Keep in original sealed container until reconstitution
Reconstituted solution
- • Refrigerate at 2–8°C after reconstitution
- • Use bacteriostatic water for multi-dose reconstitution
- • Typical stability: 14–28 days refrigerated
- • Do not freeze reconstituted solution
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| Nootropic powder vendors | Variable | Purity and form verification are important |
| Capsule suppliers | Usually higher than bulk powder | Capsules reduce but do not eliminate dose uncertainty |
| Medical withdrawal care | Can be substantial | Severe dependence may require urgent treatment |
The bottom line
Phenibut FAA is a formulation variant, not a fundamentally safer compound. It may be less acidic and more convenient for some routes, but the meaningful risks remain tolerance, dependence, withdrawal, CNS depression, and dangerous interactions.
Best for
- • Formulation comparison research
- • Users already educated on phenibut risks
- • Occasional-use risk analysis
- • Clinicians evaluating phenibut exposure history
Not for
- • Daily anxiety control
- • Combining with alcohol or sedatives
- • People with prior sedative dependence
- • Eyeballed powder dosing
Related compounds
Pancragen
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Phenibut
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Phenylpiracetam
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Pielotax
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Frequently asked questions
References
- [1] Lapin I. Phenibut (beta-phenyl-GABA): a tranquilizer and nootropic drug. CNS Drug Reviews (2001). doi: 10.1111/j.1527-3458.2001.tb00211.x PMID: 11830761
- [2] Gurley BJ, Koturbash I. Phenibut: A drug with one too many buts. Basic & Clinical Pharmacology & Toxicology (2024). doi: 10.1111/bcpt.14075 PMID: 39197876
- [3] Hardman MI, Sprung J, Weingarten TN. Acute phenibut withdrawal: A comprehensive literature review and illustrative case report. Bosnian Journal of Basic Medical Sciences (2019). doi: 10.17305/bjbms.2018.4008
- [4] Joshi YB, Friend SF, Jimenez B, Steiger LR. Dissociative Intoxication and Prolonged Withdrawal Associated With Phenibut: A Case Report. Journal of Clinical Psychopharmacology (2017). doi: 10.1097/JCP.0000000000000731 PMID: 28614159
- [5] Ahuja T, Mgbako O, Katzman C, Grossman A. Phenibut Dependence and Management of Withdrawal. Journal of Addiction Medicine (2018). PMID: 29854531
- [6] World Health Organization Expert Committee on Drug Dependence. Critical Review Report: Phenibut. World Health Organization (2021).